Abstract
Mantle cell lymphoma as a rare non-Hodgkin B-cell lymphoma can present in different clinical presentations such as an aggressive form or a more indolent picture. Treatment modality is based on multiple factors including age, presence or absence of symptoms, and comorbidities. Watchful waiting is a reasonable approach for asymptomatic patients especially in elderly. In symptomatic patients, treatment is chemo-immunotherapy followed by maintenance immunotherapy or autologous bone marrow transplant. Allogeneic bone marrow transplant has a potential benefit of cure for relapsed/refractory cases, but it has a high mortality rate. Novel treatment with agents such as ibrutinib, a Bruton tyrosine kinase inhibitor, has shown promising results in relapse/refractory cases. We extensively review the most recent data on diagnostic and therapeutic management of mantle cell lymphoma through presenting two extreme clinical scenarios.
Original language | English (US) |
---|---|
Pages (from-to) | 37-48 |
Number of pages | 12 |
Journal | Therapeutic Advances in Hematology |
Volume | 6 |
Issue number | 1 |
DOIs | |
State | Published - Feb 2015 |
Externally published | Yes |
Keywords
- chemo-immunotherapy
- ibrutinib
- mantle cell lymphoma
- transplantation
ASJC Scopus subject areas
- Hematology